NCT02015234View on ClinicalTrials.gov

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Primary Fibromyalgia
Interventions
DRUG

TNX-102 SL

TNX-102 SL 2.8 mg taken daily at bedtime.

Trial Locations (13)

17055

1001 South Market Street, Mechanicsburg

21702

71 Thomas Johnson Drive, Frederick

29650

322 Memorial Drive, Greer

32806

100 West Gore Street, Orlando

34601

16176 Cortez Boulevard, Brooksville

39202

Jackson, Jackson

43212

1275 Olentangy River Road, Columbus

44130

18660 Bagley Road, Middleburg Heights

45219

Cincinnati, Cincinnati

80239

Denver, Denver

98122

601 Broadway, Seattle

02747

370 Faunce Corner Road, North Dartmouth

01605

Worcester, Worcester

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT02015234 - 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients | Biotech Hunter | Biotech Hunter